Daily practices in chemotherapy for advanced gastric or gastroesophageal junction adenocarcinoma: METESTOMAC French prospective cohort.
cohort
gastric cancer
real life
strategy
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
03 2023
03 2023
Historique:
revised:
13
09
2022
received:
24
06
2022
accepted:
04
10
2022
pubmed:
18
11
2022
medline:
24
3
2023
entrez:
17
11
2022
Statut:
ppublish
Résumé
Around 50% of gastric cancers are diagnosed at an advanced stage. Several chemotherapy regimens are now internationally validated. Few data are available on the routine daily management of advanced gastric or gastroesophageal junction cancers. We aimed to describe chemotherapy practices, tolerance, and efficacy overall survival (OS) and Progression free survival (PFS) in a prospective French cohort. Patients starting palliative chemotherapy were prospectively enrolled in 49 French centres. The primary objective was to report and describe patients' characteristics and treatment strategies. Secondary objectives were OS, PFS, objective response rate, adverse events rate, performance status deterioration during the chemotherapy. A total of 182 patients were included; 179 were analysed. Most patients received platinium-based chemotherapy as the first treatment and FOLFIRI as second; 62.0% of patients received a second line, and 32.4% a third line. More than two thirds of Her2-positive patients were first treated with trastuzumab. The FOLFIRI regimen was the most frequently used second-line therapy. Median OS was 13.3 months, similar whatever the chemotherapy or combinations used in the first line. One- and 2-year OS increased with the number of chemotherapy lines received, from respectively 24.7% and 5.7% (1 line), to 46.9% and 12.4% (2 lines) and 88.1% and 29.9% (3 or more lines) (p < 0.0001). Our study showed that treatment strategies in France are based on a succession of doublets, making it possible to offer a second and third line of treatment more often. This treatment strategy must be taken into account for future trials with immunotherapy combinations.
Sections du résumé
BACKGROUND
Around 50% of gastric cancers are diagnosed at an advanced stage. Several chemotherapy regimens are now internationally validated. Few data are available on the routine daily management of advanced gastric or gastroesophageal junction cancers. We aimed to describe chemotherapy practices, tolerance, and efficacy overall survival (OS) and Progression free survival (PFS) in a prospective French cohort.
METHODS
Patients starting palliative chemotherapy were prospectively enrolled in 49 French centres. The primary objective was to report and describe patients' characteristics and treatment strategies. Secondary objectives were OS, PFS, objective response rate, adverse events rate, performance status deterioration during the chemotherapy.
RESULTS
A total of 182 patients were included; 179 were analysed. Most patients received platinium-based chemotherapy as the first treatment and FOLFIRI as second; 62.0% of patients received a second line, and 32.4% a third line. More than two thirds of Her2-positive patients were first treated with trastuzumab. The FOLFIRI regimen was the most frequently used second-line therapy. Median OS was 13.3 months, similar whatever the chemotherapy or combinations used in the first line. One- and 2-year OS increased with the number of chemotherapy lines received, from respectively 24.7% and 5.7% (1 line), to 46.9% and 12.4% (2 lines) and 88.1% and 29.9% (3 or more lines) (p < 0.0001).
CONCLUSION
Our study showed that treatment strategies in France are based on a succession of doublets, making it possible to offer a second and third line of treatment more often. This treatment strategy must be taken into account for future trials with immunotherapy combinations.
Identifiants
pubmed: 36394147
doi: 10.1002/cam4.5354
pmc: PMC10028027
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
5341-5351Informations de copyright
© 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
Eur J Cancer. 2011 Oct;47(15):2306-14
pubmed: 21742485
Cancer Med. 2023 Mar;12(5):5341-5351
pubmed: 36394147
J Gastrointest Oncol. 2016 Aug;7(4):499-505
pubmed: 27563438
Lancet. 2014 Jan 4;383(9911):31-39
pubmed: 24094768
Dig Liver Dis. 2018 Aug;50(8):768-779
pubmed: 29886081
Clin Colorectal Cancer. 2018 Sep;17(3):223-230
pubmed: 29980492
JAMA Oncol. 2020 Oct 1;6(10):1539-1541
pubmed: 32880639
N Engl J Med. 2008 Jan 3;358(1):36-46
pubmed: 18172173
Eur J Cancer. 2009 Apr;45(6):1042-66
pubmed: 19124239
Oncol Ther. 2017;5(1):53-67
pubmed: 28680955
Dig Liver Dis. 2021 Apr;53(4):420-426
pubmed: 33358124
Lancet. 2010 Aug 28;376(9742):687-97
pubmed: 20728210
JAMA Oncol. 2020 Oct 1;6(10):1571-1580
pubmed: 32880601
Ann Oncol. 2016 Sep;27(suppl 5):v38-v49
pubmed: 27664260
J Drug Assess. 2019 Sep 17;8(1):150-158
pubmed: 31656688
Nat Med. 2018 Sep;24(9):1449-1458
pubmed: 30013197
Cochrane Database Syst Rev. 2017 Aug 29;8:CD004064
pubmed: 28850174
J Clin Oncol. 2015 Nov 20;33(33):3874-9
pubmed: 26438119
Oncotarget. 2017 Sep 08;8(60):101383-101393
pubmed: 29254172
Lancet Oncol. 2014 Jan;15(1):78-86
pubmed: 24332238
Gastric Cancer. 2015 Jan;18(1):129-37
pubmed: 24488016
Lancet. 2015 Mar 14;385(9972):977-1010
pubmed: 25467588
Dig Liver Dis. 2018 Apr;50(4):408-410
pubmed: 29409778
Ann Oncol. 2009 Apr;20(4):666-73
pubmed: 19153121
Br J Cancer. 1999 Apr;80(1-2):269-72
pubmed: 10390007
Lancet Oncol. 2014 Oct;15(11):1224-35
pubmed: 25240821
J Clin Oncol. 2004 Nov 1;22(21):4319-28
pubmed: 15514373
J Clin Oncol. 2020 Jun 10;38(17):1919-1927
pubmed: 32208960
Ann Oncol. 2004 May;15(5):765-9
pubmed: 15111344
J Clin Oncol. 2008 Mar 20;26(9):1435-42
pubmed: 18349393
Dig Liver Dis. 2016 Sep;48(9):984-94
pubmed: 27156069
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
J Clin Oncol. 2006 Nov 1;24(31):4991-7
pubmed: 17075117
Cancer Res Treat. 2017 Jul;49(3):578-587
pubmed: 27618820
Target Oncol. 2018 Feb;13(1):107-112
pubmed: 29090377
Science. 2017 Jul 28;357(6349):409-413
pubmed: 28596308
J Clin Oncol. 2014 Nov 1;32(31):3520-6
pubmed: 25287828
Ann Oncol. 2009 Sep;20(9):1529-1534
pubmed: 19474114
J Clin Oncol. 1997 Jan;15(1):261-7
pubmed: 8996151